Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajender Reddy

Internal Medicine Hammonton, NJ Medical Doctor

NPI 1467505784 CMS profile 20654

301 Spring Garden Rd, Fl 4, Hammonton, NJ 08037

Open in the dashboard

General payments

$96,441

38 records reported · program years 2019–2025

Research payments

$4,922

Paid to them · 14 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$746,094 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Rajender Reddy of Hammonton, NJ is reported in the CMS Open Payments database as having received $96,441 across 38 general payments and $4,922 in research payments paid to them. Separately, studies naming them as principal investigator received $746,094 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,963 1
2025 Research $1,932 11
2024 General $13,495 6
2023 General $30,378 12
2022 General $32,853 11
2022 Research $1,240 1
2021 General $17,243 4
2019 General $510 4
2019 Research $1,750 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajender Reddy
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rajender Reddy were reported at $1,963. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rajender Reddy Internal Medicine median Middle half National median
2019 $510 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $17,243 $135 $37–$521 $132
2022 $32,853 $141 $42–$496 $149
2023 $30,378 $149 $45–$519 $160
2024 $13,495 $154 $47–$537 $164
2025 $1,963 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $70,970 22 payments
  2. Pfizer Limited $10,406 4 payments
  3. Mallinckrodt Hospital Products Inc. $5,799 2 payments
  4. AstraZeneca UK Limited $5,500 4 payments
  5. Novo Nordisk AS $2,325 1 payment
  6. Deciphera Pharmaceuticals Inc. $930 1 payment
  7. Spark Therapeutics, Inc. $510 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $80,750 18 payments
  2. Travel and Lodging $14,661 14 payments
  3. Food and Beverage $1,031 6 payments
Products named General payments · program years 2019–2025
  1. XYNTHA $10,406 4 payments
  2. BENEFIX $10,406 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $1,932 11 payments
  2. Bausch Health US, LLC $1,750 2 payments
  3. Deciphera Pharmaceuticals Inc. $1,240 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

46

Median for Internal Medicine: 777

Drug cost

$685

Median for Internal Medicine: $73,373

Branded share of claims

0%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Levothyroxine Sodium Generic 22 $363
Pantoprazole Sodium Generic 12 $186
Lisinopril Generic 12 $136

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Records

52 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record